Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly-Reference-Cited by-同舟云学术

Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

Published:2002-01 Issue:1 Volume:56 Page:65-71
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:

Author:

Amato Giovanni,Mazziotti Gherardo,Rotondi Mario,Iorio Sergio,Doga Mauro,Sorvillo Francesca,Manganella Giovanni,Di Salle Francesco,Giustina Andrea,Carella Carlo

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.0300-0664.2001.01438.x/fullpdf

Reference32 articles.

1. Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study;Arosio;European Journal of Endocrinology,1995

2. Preoperative treatment of acromegaly with long-acting somatostatin analogue SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate;Barkan;Journal of Clinical Endocrinology and Metabolism,1988

3. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide;Caron;Journal of Clinical Endocrinology and Metabolism,1997

4. Comparison of actrotide acetate LAR and lanreotide SR inpatients with acromegaly;Chanson;Clinical Endocrinology,2000

5. How many surgeons to operate on acromegalic patients;Clayton;Clinical Endocrinology,1999

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management;Journal of Endocrinological Investigation;2024-05-29

2. Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults;Cochrane Database of Systematic Reviews;2024-02-06

3. Modern approach to resistant acromegaly;Endocrine;2023-02-15

4. Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas;Pituitary;2022-08-27

5. Replacement of prolonged-acting octreotide with lanreotide autogel 120 mg in patients with Acromegaly in real clinical practice;Meditsinskiy sovet = Medical Council;2022-06-19